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Abstract—A current challenge in cellular signaling is to decipher the complex intracellular spatiotemporal organization that
any given cell type has developed to discriminate among different external stimuli acting via a common signaling
pathway. This obviously applies to cAMP and cGMP signaling in the heart, where these cyclic nucleotides determine
the regulation of cardiac function by many hormones and neuromediators. Recent studies have identified cyclic
nucleotide phosphodiesterases as key actors in limiting the spread of cAMP and cGMP, and in shaping and organizing
intracellular signaling microdomains. With this new role, phosphodiesterases have been promoted from the rank of a
housekeeping attendant to that of an executive officer. (Circ Res. 2006;99:816-828.)
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The cyclic nucleotides cyclic adenosine 3,5-monophosphate(cAMP) and cyclic guanosine 3,5-monophosphate
(cGMP) were identified more than 4 decades ago.1,2 Since then,
many studies have appeared on how these 2 second messengers
are synthesized or degraded, what makes their level go up or
down, what they do to target effectors by either covalent
(phosphorylation) or noncovalent (direct binding to proteins,
such as ion channels or guanine-nucleotide-exchange factors)
mechanisms, and how they affect a countless number of cellular
functions.3–6 In certain tissues and organs, the cyclic nucleotide
pathways have been so fully explored over the years that one can
wonder what else is there to be found. This is the case for cAMP
in the heart, where it plays a key role in the sympathetic
nerve/-adrenergic receptor (-AR)/adenylyl cyclase (AC)/pro-
tein kinase A (PKA) axis that serves to stimulate cardiac rhythm
(chronotropy) as well as contractile force (inotropy) and relax-
ation (lusitropy).7 Yet, there are a number of questions that have
always made us wonder but have only lately begun to receive the
attention they deserve: how so many different receptors coupled
to cAMP or cGMP signaling pathway manage to achieve
specific cellular responses? What is the purpose of the different
adenylyl and guanylyl cyclases present in the same cell? Why do
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so many different cyclic nucleotide phosphodiesterases (PDEs)
coexist to hydrolyze cAMP and cGMP? Do these cyclic nucle-
otides and their respective effectors freely diffuse inside the cell
or are they localized? Does a cyclic nucleotide compartmenta-
tion have any physiological or pathophysiological importance?
Some of these questions have received answers in recent studies
combining molecular biology, fluorescence imaging, and elec-
trophysiological approaches. In particular, compelling evidence
is now accumulating about the formation of molecular com-
plexes (signalosomes) in distinct cellular compartments that
influence cyclic nucleotide signaling. Although this review
summarizes some of the recent evidence supporting a localized
cyclic nucleotide signaling in cardiomyocytes, the reader is
encouraged to read other recent reviews on related issues.4,5,8–13
Cyclic AMP Synthesis
Cyclic AMP is synthesized from ATP by at least 9 closely
related isoforms of adenylyl cyclases (ACs).14,15 In heart,
AC5 and AC6 represent the dominant isoforms,14 although
AC7 and AC9 may be present at the mRNA level,16,17 and
AC4 both at the mRNA and protein level.18,19 AC5 and AC6
share strong similarities, both in sequence and functional
characteristics: both are activated by Gs subunits and fors-
kolin and inhibited by Gi and G subunits,20,21 Ca2
ions,22,23 and PKA phosphorylation.14,15,20,24,25 However,
AC5 and AC6 differ in their regulation by PKC: AC5 is
activated,26 whereas AC6 is inhibited,27 by PKC phosphory-
lation. The lack of specific antibody against each isoform
does not allow to examine the specific distribution of AC5
and AC6 at the membrane. However, immunofluorescence
staining of isolated adult ventricular myocytes using a com-
mon AC5/6 antibody demonstrated a preferential localization
of these proteins in T-tubular membranes.28,29
Do AC5 and AC6 play distinct roles in cardiac myocytes?
Although, to our knowledge, a dominant negative approach
has never been attempted to address that question specifi-
cally, several indirect evidence suggest that this is the case.
First, AC5 and AC6 show a different pattern of expression
during embryonic and postnatal cardiac development, at least
at the mRNA level: in rat heart, both isoforms are equally
expressed at fetal stage but AC5 mRNA progressively accu-
mulates during ontogenic development, whereas AC6 mRNA
remains unchanged.30 Second, AC6 and AC5 expression
follows a different pattern of downregulation in several
models of heart failure.31–33 Finally, studies performed in
animal models with a cardiac-directed overexpression of
AC534,35 or AC6,36–39 or with AC5 inhibition by gene
invalidation40,41 or specific pharmacological inhibition,42,43
suggest that the 2 cyclases exert opposite effects, respec-
tively, beneficial for AC6 and deleterious for AC5, on cardiac
cell survival,37,43 intracellular Ca2 handling,39,41 and contrac-
tile function.38,41,44 The finding that AC5 and AC6 may have
specific roles suggests that the 2 enzymes are located in
distinct compartments, interacting with distinct receptors or
target proteins. For instance, purinergic and 1-adrenergic
stimulations differentially activate AC isoforms in rat cardio-
myocytes, AC5 being the specific target of the purinergic45
and AC6 of the 1-adrenergic stimulation.46,47 Also, colocal-
ization of AC and KATP channels was shown to induce a local
regulation of the KATP channel current by PKA phosphoryla-
tion,48 or local ATP depletion.49
Cyclic GMP Synthesis
Cyclic GMP synthesis is controlled by 2 types of guanylyl
cyclases (GCs) that differ in their cellular location and
activation by specific ligands: a particulate GC (pGC) present
at the plasma membrane, which is activated by natriuretic
peptides (NPs) such as atrial (ANP), brain (BNP), and C-type
natriuretic peptide (CNP)50–52; and a soluble guanylyl cyclase
(sGC) present in the cytosol and activated by nitric oxide
(NO).52,53 NPs exert their effects by 3 single transmembrane
NP receptors: NPR-A, NPR-B, and NPR-C. Both NPR-A and
NPR-B have intrinsic GC activity in their cytosolic domain
and catalyze the synthesis of cGMP from GTP.54 NPR-C
lacks enzymatic activity but controls local NP concentrations
through constitutive receptor-mediated internalization and
degradation55 and acts via Gi-dependent mechanisms.56 All
receptors can be activated by the 3 NPs but NPR-A has a
higher affinity for ANP and BNP, whereas NPR-B is more
specific for CNP.57
Do pGC and sGC play distinct roles in cardiac myocytes? A
number of studies clearly support this assumption. For instance,
in frog ventricular myocytes, sGC activation causes a pro-
nounced inhibition of L-type Ca2 current (ICa,L) on cAMP
stimulation,58 whereas pGC activation has little effect.59 In rabbit
atria, pGC activation caused a larger cAMP accumulation (via
phosphodiesterase 3 [PDE3] inhibition), cGMP efflux, and ANP
release than activation of sGC.60 In mouse ventricular myocytes,
both pGC and sGC activation exerted similar negative inotropic
effects. These effects on cell contraction were mediated by a
cGMP-dependent pathway involving cGMP-dependent protein
kinase (PKG) and PDEs. However, pGC activation decreased
Ca2 transients, whereas sGC activation had marginal effects,61
similar to what was found in pig airway smooth muscle.62 These
data suggest that pGC signaling works mainly to decrease
intracellular Ca2 level, whereas sGC signaling mainly decreases
Ca2 sensitivity. Evidence for different functional effects of
cGMP produced by either sGC or pGC also come from studies
in noncardiac cell types. For instance, in human endothelial cells
from umbilical vein, activation of sGC induces a more efficient
relaxation than does pGC activation.63 In airway smooth muscle
cells from pig, stimulation of pGC induces relaxation exclu-
sively by decreasing intracellular Ca2 concentration, whereas
sGC stimulation decreases both Ca2 concentration and sensi-
tivity of the myofilaments.62 In human embryonic kidney, ANP,
but not S-nitroso-L-acetyl penicillamine (SNAP) (an NO donor)
induces a recruitment of PKG to plasma membrane and ampli-
fies GC activity of the NPR-A receptor.64
Cyclic Nucleotide Hydrolysis
The level of intracellular cAMP and cGMP is not only
regulated by their synthesis but also by their degradation
(Figure 1). This is achieved by cyclic nucleotide PDEs, a
superfamily of metallophosphohydrolases that specifically
cleave the 3,5-cyclic phosphate moiety of cAMP and/or
cGMP to produce the corresponding 5-nucleotide. In this
way, cGMP is converted into 5-GMP and cAMP into
5-AMP, hence producing inert molecules, destroying the
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second messenger activity of cyclic nucleotides, and control-
ling or limiting the activity of these molecules on their
substrates such as PKA, PKG, etc.
PDEs vary in their substrate specificity, mechanism of action
and subcellular location.65,66 Cardiac PDEs fall into at 5 five
families (Figure 1): PDE1, which hydrolyzes both cAMP and
cGMP, is activated by Ca2-calmodulin, and is essentially
expressed in a nonmyocyte fraction of cardiac tissue67; PDE2,
which also can hydrolyze both cAMP and cGMP and is
stimulated by cGMP binding to amino terminal allosteric regu-
latory sites known as GAF domains68; PDE3, which has a
similar affinity for cAMP and cGMP but a higher Vmax for the
former, making it a cGMP-inhibited cAMP-PDE; PDE4, which
is specific for cAMP; and PDE5, which is specific for cGMP.
Within these PDE families, multiple isoforms are expressed,
either as products of different genes or as products of the same
gene through alternative splicing and/or by differential use of
translation starting sites. Thus, until now, at least a dozen of
different PDE isoforms have been found in heart: PDE1C69,70;
PDE2A71; PDE3A-136, PDE3A-118, and PDE3A-9472;
PDE3B73; PDE4B74; PDE4D3, PDE4D5, PDE4D8, and
PDE4D975; and PDE5A.76,77 A last isoform (PDE9A), highly
specific of cGMP, has been shown to be expressed at the mRNA
level in human78 but not mouse heart.79 All PDE isoforms but
PDE9A78,79 are inhibited by xanthine derivatives such as
3-isobutyl-1-methylxanthine (IBMX), and a number of drugs
have been developed as selective PDE inhibitors65,66: EHNA80
and Bay 60-755081 for PDE2; milrinone, cilostamide, and other
bipyridines for PDE366; rolipram and Ro 20-1724 for PDE466;
sildenafil, tadalafil, and vardenafil for PDE5.66,82 These drugs
provide valuable pharmacological tools for exploring the func-
tional role of each PDE family in cyclic nucleotide signaling and
targeting.
Cyclic AMP and Cyclic GMP Effectors
The cardiac effects of cAMP are classically attributed to
PKA-mediated phosphorylation of a myriad of proteins, some
of which are critically involved in excitation/contraction
coupling. These include L-Type Ca2 channels (LTCCs,
which underlies the ICa,L),83,84 phospholamban (PLB),85,86
ryanodine receptor 2 (RyR2),87 the phosphatase 1 inhibi-
tor,88,89 and a number of contractile proteins, such as troponin
I (TnI), and myosin binding protein C.7,90 PKA also controls
gene expression through the activation of the cAMP response
element-binding protein (CREB) family of transcription fac-
tors.91 Cyclic AMP regulates other targets in a PKA-
independent manner, like the exchange protein directly acti-
vated by cAMP (Epac)92,93 and HCN cyclic nucleotide gated
ion channels.94,95 The consequence of an acute rise in intra-
cellular cAMP concentration is in most cases a positive
chronotropic, inotropic, or lusitropic effect, or a combination
of 2 or more of these. These effects are counteracted by
acetylcholine (ACh) released from sympathetic nerves. ACh
binds to muscarinic M2 receptors, which inhibit cAMP
synthesis through pertussis toxin–sensitive Gi proteins.96
Cyclic GMP is often represented as the mirror of cAMP. In
the short term, cGMP usually exerts negative metabolic as well
as inotropic effects97,98 and opposes most of the positive effects
of cAMP on cardiac function.99 On NO or NP action, cGMP
accumulates and interacts with several targets, such as PKG and
PDEs (Figure 1), which attenuate the -adrenergic re-
sponse.99,100 In the long term, eg, during chronic cGMP pathway
stimulation by NO101,102 or NPs,103,104 or in transgenic mice with
cardiac overexpression of endothelial or inducible NO syn-
thases,105 cGMP possesses antihypertrophic effects.106–108
Compartmentation of Cyclic
Nucleotide Signaling
Several observations have suggested that some components
within the cyclic nucleotide-signaling pathway are colocal-
ized to discrete regions of the plasma membrane such as
caveolae109–112 and transverse tubules,28,29 thereby allowing
rapid and preferential modulation of cAMP and cGMP
production within a defined microenvironment (Figure 2).
Figure 1. Cyclic AMP and cGMP pathways in cardiac myocytes.
The diagram illustrates the enzymes involved in cAMP and
cGMP synthesis and degradation and the complex interplay
between the 2 signaling pathways in cardiac myocytes (in red
for cAMP and in blue for cGMP). This “classical” representation
does not account for signaling microdomains.
Figure 2. Intracellular distribution of PDE isoforms and macro-
molecular complexes potentially involving PDE activity in cyclic
nucleotide compartmentation in cardiac myocytes.
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With the discovery of A-kinase anchoring protein
(AKAP),113,114 it has become apparent that intracellular tar-
geting of PKA as well as the preassembly of components of
signaling pathways in clusters or on scaffolds are important
for the speed and organization of cAMP signal transduction
events.12 However, one would wonder how specificity is
maintained when small diffusible molecules such as cAMP
and cGMP are generated during signaling cascade. Localized
cyclic nucleotide signals may be generated by interplay
between discrete production sites and restricted diffusion
within the cytoplasm. In addition to specialized membrane
structures that may circumvent cAMP and cGMP spread-
ing,8,115 degradation of these cyclic nucleotides by PDEs
appears critical for the formation of dynamic microdomains
that confer specificity of the response (Figure 2).116–119
The first evidence for a compartmentation of cAMP signaling
in heart comes from experiments made almost 30 years ago in
isolated perfused hearts.120–122 Important differences were ob-
served when comparing hearts perfused with different agonists
activating the cAMP cascade, particularly via 1-AR and pros-
taglandin E1 receptor (PGE1-R): with isoproterenol (ISO), cAMP
is elevated, the force of contraction is enhanced, soluble and
particulate PKA are activated, and the activity of phosphorylase
kinase and glycogen phosphorylase is increased; with PGE1,
cAMP content and soluble PKA activity are also increased, but
there is no change in contractile activity or in the activities of
PKA substrates that regulate glycogen metabolism.122,123 Similar
results were reproduced in isolated myocytes.124 The situation is
even more complex if one considers that a given cardiac
myocyte expresses many other Gs-coupled receptors, besides
1-ARs and PGE1-Rs, that increase cAMP but produce different
effects. For instance, adult rat ventricular myocytes also express
2-ARs, glucagon receptors (Glu-Rs), and glucagon-like
peptide-1 receptors (GLP1-Rs). 2-AR stimulation increases
contractile force but does not activate glycogen phosphorylase125
and does not accelerate relaxation126,127 (however, see Bartel et
al125); Glu-R stimulation activates phosphorylase and exerts
positive inotropic and lusitropic effects, but the contractile
effects fade with time128; GLP1-R stimulation exerts a modest
negative inotropic effect despite an increase in total cAMP
comparable to that elicited by a 1-adrenergic stimulation.129
These results clearly show that the cell is able to distinguish
between different stimuli acting on a common signaling cascade.
One possible way to achieve that distinction is to confine the
cyclic nucleotide signaling cascade to distinct intracellular com-
partments that may differ depending on the stimulus used.
Methods to Study Cyclic Nucleotide
Compartmentation in Intact Cardiomyocytes
During 20 years, most of the evidence supporting a compart-
mentation of cyclic nucleotide signaling in cardiac prepara-
tions was gathered using biochemical assays in fractionated
dead tissues or cells. However, during the last decade, a
number of sophisticated methods have been developed which
now allow to evaluate the role of cyclic nucleotide compart-
mentation in intact living cells.
The first such method combines a classical whole-cell
patch-clamp recording of ICa,L (as a probe for cAMP/PKA
activity) with a double-barreled microperfusion system.116
This allows to test the effect of a local application of a
receptor agonist on ICa,L in the part of the cell exposed to the
agonist and compare it with the response of the Ca2 channels
located on the nonexposed part. This method provided the
first evidence for a local elevation of cAMP in response to a
2-adrenergic stimulation in frog ventricular cells as com-
pared with a uniform elevation of cAMP in response to
forskolin, a direct AC activator.116 A similar conclusion was
reached using the cell-attached configuration of the patch-
clamp technique in mammalian cardiomyocytes130 and neu-
rons131 by applying a 2-adrenergic agonist either inside or
outside the patch pipette while recording single LTCC activ-
ity in the patch of membrane delimited by the pipette.
More direct methods have been developed to monitor
cyclic nucleotide changes using fluorescent probes and im-
aging microscopy. The first such probe was FlCRhR, a
fluorescent indicator for cAMP that consists of PKA in which
the catalytic (C) and regulatory (R) subunits are each labeled
with a different fluorescent dye, respectively, fluorescein and
rhodamine.132 Fluorescence resonance energy transfer
(FRET) occurs in the holoenzyme complex R2C2 but when
cAMP binds to the R subunits, C subunits dissociate, and the
FRET signal is impaired. The change in shape of the
fluorescence emission spectrum allows cAMP concentrations
to be visualized in real-time in single living cells, as long as
it is possible to microinject the cells with the labeled
holoenzyme.132 This in itself represents a major technical
challenge, particularly in cardiomyocytes,133 and has
prompted the search for genetically encoded probes. A cAMP
probe has been generated using the same principle as FlCRhR
but by fusing a yellow fluorescent protein (YFP) and a cyan
fluorescent protein (CFP) to R and C subunits, respective-
ly.134 On a similar principle, through genetic modifications of
other target effectors, a number of different probes are now
available for real-time measurements of cAMP135–138 and
cGMP139,140 in living cells, including cardiac
myocytes.74,77,119,141,142
A third type of approach is based on the use of recombinant
cyclic nucleotide-gated channel (CNG) channels as cyclic
nucleotide biosensors. The methodology was developed in a
series of elegant studies in model cell lines for the measure-
ment of intracellular cAMP.115,143,143,144 This method uses
wild-type or genetically modified  subunits of rat olfactory
CNG channel (CNGA2), which form a cationic channel
directly opened by cyclic nucleotides. Adult cardiac myo-
cytes infected with an adenovirus encoding the native or
modified channels elicit a nonselective cation current when,
respectively, cGMP145 or cAMP concentration146,147 rises
beneath the sarcolemmal membrane.
Role of PDEs in Cyclic
Nucleotide Compartmentation
Probably the first evidence for a contribution of PDEs to
intracellular cyclic nucleotide compartmentation comes from
a study in guinea pig perfused hearts.148 In that study, ISO
was shown to significantly increase intracellular cAMP,
cardiac contraction and relaxation, as well as phosphorylation
of PLB and TnI, whereas the nonselective PDE inhibitor
IBMX or the PDE3 inhibitor milrinone enhanced contraction
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and relaxation but had little or no effect on phosphorylation
of PLB and TnI, despite a relatively large increase in tissue
cAMP level.148 These results were attributed to a functional
cellular compartmentation of cAMP and PKA substrates
resulting from a different expression of PDEs at the mem-
brane and in the cytosol.149 Many subsequent studies have
examined the degree of accumulation of cAMP or activation
of cAMP dependent phosphorylation in particulate and solu-
ble fractions of cardiac myocytes. In an elegant such study
performed in canine ventricular myocytes, Hohl and Li
demonstrated that cytosolic and particulate pools of cAMP
are differently affected by various treatments designed to
raise intracellular cAMP.150 These authors have demonstrated
that approximately 45% of the total cAMP is found in the
particulate fraction in response to ISO, but this fraction
declined to 20% when IBMX was added to ISO, although
total cAMP still increased approximately 3-fold. This sug-
gests that cAMP-specific PDE activity resides predominantly
in the cytosolic compartment and is responsible for the
particulate cAMP microdomains generation that cause Ca2
mobilization and cardiac inotropic state through particulate
PKA activation and phosphorylation of membrane and con-
tractile proteins. Even if the cell is able to generate and
accumulate cAMP that exceeds what is needed for a maximal
physiologic response under PDE inhibition and forskolin
stimulation, only particulate cAMP content determines the
physiological response. These results show that PDEs main-
tain the specificity of the -adrenergic response by limiting
the amount of cAMP diffusing from membrane to cytosol.
These biochemical data are in full agreement with func-
tional studies in frog ventricular myocytes, where the effect
of a local application of ISO on ICa,L was tested in the presence
or absence of IBMX.116 Although the ICa,L response to ISO
was much higher at the side of ISO application than in the
nonexposed part of the cell, complete PDE inhibition in the
presence of ISO released the cAMP signal to activate LTCCs
in the remote part of the cell. Thus, these results suggest that
PDE activity contributes to generate cAMP microdomains
involved in the -adrenergic stimulation of Ca2 channels. A
recent study using recombinant CNG channels demonstrates
that this also applies to other Gs-coupled receptors (1-AR,
2-AR, PGE1-R, Glu-R), with a specific pattern of PDE
activity determining the specificity of the cAMP signals
generated by each receptor (Figure 3).147 For instance, cAMP
elicited by 1-AR is regulated by PDE3 and by PDE4,
whereas cAMP signal generated by Glu-R is exclusively
regulated by PDE4. In mouse neonatal cardiomyocytes,
PDE4D was shown to selectively impact cAMP signaling by
2-AR, while having little or no effect on 1-AR signaling.151
Indeed, although 2-AR activation leads to an increase in
cAMP production, the cAMP generated does not have access
to the PKA-dependent signaling pathways by which the
1-AR regulates the contraction rate, unless PDE4D is inhib-
ited or its gene has been invalidated.151
The use of selective inhibitors of the dominant cardiac
PDE isoforms has allowed to evaluate the contribution of 4
different PDE families in the compartmentation of cAMP and
cGMP pathways in cardiac myocytes: PDE2, PDE3, PDE4,
and PDE5. Coimmunoprecipitation experiments have further
demonstrated that macromolecular complexes exist at differ-
ent locations within a cardiac myocyte that include PDE3 and
PDE4 isoforms, forming local signaling microdomains (Fig-
ures 2 and 3). The role of each individual PDE family in these
microdomains is reviewed below.
Phosphodiesterase 2
Cyclic GMP–stimulated PDE (PDE2) hydrolyzes both cAMP
and cGMP with low affinity. A single PDE2 variant, PDE2A,
is expressed in cardiac tissues and in isolated cardiomyocytes
of several species, including rat, bovine, and human.152–154
PDE2 is found both in the cytosol and associated to func-
tional membrane structures (plasma membrane, sarcoplasmic
reticulum [SR], Golgi, nuclear envelope).65 Although PDE2
activity is relatively small compared with other cardiac PDEs,
such as PDE3 and PDE4, its presence at the plasma mem-
brane contributes to regulate the activity of cardiac LTCCs
when cGMP level is increased.99 This was first demonstrated
in frog ventricular myocytes dialyzed with cAMP and cGMP,
where PDE2 is able to hydrolyze cAMP and hence reduce
ICa,L on application of cGMP, even when 5 mol/L cAMP
is continuously dialyzed inside the cell via the patch pi-
pette.155,156 Increased knowledge of the contribution of PDE2
to cardiac function has accumulated after the demonstration
that the adenosine deaminase inhibitor erythro-9-(2-hydroxy-
3-nonyl)adenine (EHNA) behaves as a selective PDE2 inhib-
itor.80,157 EHNA reverses the inhibitory effect of high con-
centrations of cGMP or NO donors on ICa,L in frog
ventricular80,158 and human atrial myocytes.159,160 EHNA
alone stimulates basal ICa,L in isolated human atrial myo-
cytes,161 indicating a possible role of basal guanylyl cyclase
activity in these cells.
The role of PDE2 in cyclic nucleotide compartmentation
was first examined in frog cardiac myocytes, using the
double-barreled microperfusion technique and local applica-
tions of NO donors and/or EHNA on ICa,L stimulated by
ISO.158 The results of that study demonstrated that local
stimulation of soluble guanylyl cyclase by NO leads to a
strong local depletion of cAMP near the LTCCs caused by
Figure 3. PDE-dependent cAMP compartmentation. Activation
of different Gs-coupled receptors leads to AC activation and
cAMP production in different compartments delimited by differ-
ent subsets of PDE isoforms. (For more details, see Rochais et
al.146)
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activation of PDE2 but only to a modest reduction of cAMP
in the rest of the cell. This may be explained by the existence
of a tight microdomain among -ARs, LTCC, and PDE2
(Figure 2).158 A similar conclusion was reached recently in rat
neonatal cardiomyocytes, using the FRET-based imaging
technique.142
PDE2 is not only involved in the control of subsarcolemmal
cAMP concentration but also controls the concentration of
cGMP in that compartment. Indeed, a recent study performed in
adult rat ventricular myocytes using the CNG technique com-
pared the effects of activators of pGC (using ANP or BNP) and
sGC (using NO donors) on subsarcolemmal cGMP signals and
the contribution of PDE isoforms to these signals.145 The main
result of that study is that the “particulate” cGMP pool is readily
accessible at the plasma membrane, whereas the “soluble” pool
is not, and that the particulate pool is under the exclusive control
of PDE2 (Figure 2).145 Therefore, differential spatiotemporal
distributions of cGMP may contribute to the specific effects of
natriuretic peptides and NO donors on cardiac function.
Phosphodiesterase 3
Cyclic GMP inhibition of PDE3 can lead to cAMP increase
and to activation of cardiac function.162 This mechanism
accounts for the stimulatory effect of low concentrations of
NO donors or cGMP on ICa,L in human atrial myocytes.159,160
However, a recent study performed in perfused beating rabbit
atria demonstrated that, depending on whether cGMP is
produced by pGC or sGC, the effects on cAMP levels, atrial
dynamics, and myocyte ANP release are different, although
in both cases the effects are attributable to PDE3 inhibition.60
These results suggest that cGMP/PDE3/cAMP signaling pro-
duced by pGC and sGC is compartmentalized.60 The role of
PDE3 in cyclic nucleotide compartmentation likely depends
on its intracellular distribution. PDE3 is present in both
cytosolic and membrane fractions of cardiac myocytes, with
important species and tissue differences.65,163 For instance, in
dog heart, all PDE3 activity revealed in the membrane
fraction appears to be associated with the SR membrane.164
Inhibition of PDE3 under such conditions could lead to
localized increases in cAMP and PKA pools, leading to
increased PLB phosphorylation (Figure 2).
Three isoforms of PDE3 have been identified in human
myocardium.72 They appear to be generated from PDE3A
gene and localize to different intracellular compartments:
PDE3A-136 is present exclusively in microsomal fractions,
whereas PDE3A-118 and PDE3A-94 are both present in
microsomal and cytosolic fractions.165 The presence of dif-
ferent PDE3A isoforms in cytosolic and microsomal fractions
of cardiac myocytes is especially interesting in view of the
facts that cAMP metabolism in these compartments can be
regulated in an independent manner and that changes in
cAMP content in these compartments correlate with changes
of different physiological parameters, such as intracellular
Ca2 homeostasis and contractility.110,166 These observations
are relevant in a physiological context because competitive
inhibitors of PDE3 confer short-term hemodynamic benefits
but adversely affect long term survival in dilated cardiomy-
opathy.167,168 This biphasic response is likely to result from an
increase in the phosphorylation of a large number of PKA
substrates, some of which may contribute to the beneficial
effects (phosphorylation of PLB), whereas others contribute
to the adverse effects (phosphorylation of LTCC, RyR2, and
CREB). If one would suppose that different isoforms regulate
different proteins in response to different signals, logically
agents capable of selectively activating or inhibiting individ-
ual PDE3A isoforms may have advantages over currently
available nonselective PDE3 inhibitors in therapeutic appli-
cations. For instance, an agent that selectively inhibits SR-
associated PDE3A-136 might preserve intracellular Ca2
cycling and contractility in patients taking -AR antagonists,
without concomitant arrhythmogenic effects.72,168
Another mechanism that may participate in the detrimental
effect of PDE3 inhibitors on cardiac function is apoptosis.169
PDE3A is downregulated in heart failure,170 and this leads to
the induction of the proapoptotic transcriptional repressor
ICER (Inducible Cyclic AMP Early Repressor) in a CREB-
dependent manner (Figure 2).169 Elevated ICER represses
antiapoptotic proteins such as Bcl-2 and the PDE3A gene
itself, thus creating a positive feedback loop that maintains
reduced PDE3A levels and elevated ICER levels.171 Interest-
ingly, PDE4 inhibition does not modulate CREB and ICER,
and is not proapoptotic, thus providing another example of
cAMP compartmentation in cardiomyocytes.169
In addition to PDE3A, cardiac myocytes also express a
PDE3B isoform, at least in mouse.73 Of particular interest is the
finding that this isoform forms a complex at the cardiac
sarcolemmal membrane with the G-protein coupled, receptor-
activated phosphoinositide 3-kinase  (PI3K) (Figure 2).73
Ablation of PI3K in mice (PI3K/) induces an exacerbated
heart failure in response to aortic constriction, which appears to
be attributable to a PDE3B inhibition and to an excess of cAMP.
But mice carrying a targeted mutation in the PI3K gene causing
loss of kinase activity (PI3KKD/KD) exhibit normal cardiac
contractility associated with normal cAMP levels after aortic
stenosis compared with PI3K/. Therefore, PI3K does not
activate PDE3B via its kinase activity, but rather serves as an
anchoring protein, which recruits PDE3B into a membrane
compartment, where cAMP homeostasis shapes the chronic
sympathetic drive.73
Phosphodiesterase 4
The PDE4 family is encoded by 4 genes (A, B, C, and D) that
generate approximately 20 different isoforms, each of which
is characterized by a unique N-terminal region.172,173 Tran-
scripts for PDE4A, PDE4B, and PDE4D isoforms were found
in rat heart.69,74,75,154 In the PDE4D family, mRNA for
PDE4D1, PDE4D2, PDE4D3, PDE4D5, PDE4D7, PDE4D8,
and PDE4D9 is present in rat heart,69,75 but only PDE4D3,
PDE4D5, PDE4D8, and PDE4D9 are expressed as proteins
and active enzymes.75
An emerging theme in PDE4 action is that individual
isoforms appear to be restricted to defined intracellular
microenvironments, thus regulating particular sets of intra-
cellular processes (Figure 2).12,173–175 Compartmentation of
PDE4 isoforms is mediated by their unique N-terminal
domains, which provide the “postcode” for cellular localiza-
tion.11 For instance, PDE4A1 contains a lipid-binding do-
main, TAPAS, with specificity for phosphatidic acid that
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serves to target this PDE to specific cellular membranes.176 In
the heart, PDE4D3 is targeted to sarcomeric region of
cardiomyocytes through binding to an anchor protein called
myomegalin,177 and to the perinuclear region through binding
to muscle AKAP (mAKAP).178 This latter complex is inter-
esting because mAKAP not only binds PKA and PDE4D3 but
also Epac1 and extracellular signal-regulated kinase 5
(ERK5).179 The 3 functionally distinct cAMP-dependent en-
zymes contained in this macromolecular complex (PKA,
PDE4D3, and Epac1) respond to cAMP in different ranges of
concentrations: PKA responds to nanomolar concentrations
and would become activated early; PDE4D3 (Km, 1 to
4 mol/L), and Epac1 (Kd 4 mol/L) would become activated
once cAMP concentrations reached micromolar levels. Con-
versely, inactivation of PDE4D3 and Epac1 would precede
PKA holoenzyme reformation as cAMP levels decline.179
Besides, phosphorylation of PDE4D3 by PKA on Ser54
enhances its activity75,173 and on Ser13 increases its affinity to
mAKAP,180 whereas phosphorylation by ERK5 on Ser579
suppresses its activity.179 Therefore, when Epac1 is activated
by cAMP, it mobilizes Rap1, which suppresses ERK5 acti-
vation and relieves the inhibition of PDE4D3. With such fine
tuning, this complex provides spatial control of PKA signal-
ing by mAKAP anchoring and temporal control and termi-
nation of the cAMP signaling event by PDE activity in the
immediate vicinity.174,178 This compartment of cAMP signal-
ing in the perinuclear region may control the release of C
subunit into the nucleus178,181 and hence gene regulation.174
The same PDE4D3 was also found recently to be an
integral component of the RyR2/Ca2-release channel com-
plex at the SR membrane (Figure 2).182 In addition to RyR2
and PDE4D3, this complex is composed of mAKAP, PKA,
FKBP12.6 (calstabin2, a negative modulator or channel-
stabilizing subunit of RyR2), and the protein phosphatases
PP1 and PP2A.183,184 PKA phosphorylation of Ser2809 on
RyR2 increases the open probability of the Ca2-release
channel and decreases the binding affinity for the channel-
stabilizing subunit calstabin2, contributing to SR Ca2 store
depletion.184 Of particular interest is the observation that
heart failure in patients and animal models is accompanied by
PKA hyperphosphorylation of RyR2, which makes RyR2
channels “leaky,” hence promoting cardiac dysfunction and
arrhythmias.184 Two sets of evidence indicate that this is
attributable to a reduction in PDE4D3 activity in the RyR2
complex182: first, PDE4D3 levels in the RyR2 complex
appear reduced in failing human hearts182; second, genetic
inactivation of PDE4D in mice is associated with a cardiac
phenotype comprised of a progressive, age-related cardiomy-
opathy, and exercise-induced arrhythmias, despite normal
global cAMP signaling.182 These results emphasize the im-
portance of cAMP signaling microdomains and point to the
intriguing possibility that deregulation of specific compart-
ments may lead to a disease state.
A final example of a complex around a PDE4 isoform in
heart is that formed by PDE4D5 and -arrestins (Figure 2).185
-Arrestins are scaffold proteins that initiate desensitization
of 2-AR (as well as several other G protein–coupled
receptors) by translocating from the cytosol to the plasma
membrane, where they directly bind the activated receptors.
Recent studies have shown that -arrestins can form stable
complexes with all 4 PDE4 subfamilies in cytosol185 but that
PDE4D5 possesses a unique amino-terminal region that
confers preferential interaction with -arrestins.11,175,186,187
The specific role of this PD4D5/-arrestin interaction in the
2-AR signaling cascade comes from a unique feature of this
particular receptor, which can couple to both Gs and Gi.188 On
agonist challenge, 2-AR couples to Gs that activates AC,
thereby elevating local cAMP concentration and activating
membrane PKA anchored to AKAP-79.187 PKA in turn
phosphorylates the 2-AR, which triggers a shift in its
coupling from Gs to Gi, hence activating ERK through a
Src-regulated pathway.189 Therefore, recruitment by the acti-
vated 2-AR of the PD4D5/-arrestin puts a brake in the PKA
phosphorylation of the receptor, and prevents its shift to
Gi-signaling cascade; conversely, disruption of this complex
enhances PKA phosphorylation of the 2-AR, leading to a
dramatic change in its function.189,190
Phosphodiesterase 5
PDE5 is highly expressed in vascular smooth muscle, and its
inhibition is a primary target for the treatment of erectile
dysfunction and pulmonary hypertension.82,191 Although the
contribution of PDE5 to the regulation of cardiac function is
a matter of debate,70,98,192 there is evidence for PDE5 expres-
sion in cardiac myocytes, both at the mRNA193 and protein
level.76,77 Recently, PDE5 inhibition using sildenafil (Viagra)
was shown to decrease the -adrenergic stimulation of
cardiac systolic and diastolic function in dog,76 mouse,77 and
human98,194 as well as the -stimulation of ICa,L in guinea pig
ventricular myocytes.195 In mouse ventricular myocytes, sil-
denafil was shown to inhibit apoptosis196 and to reduce infarct
size following ischemia/reperfusion in the myocardium.197
Moreover, chronic exposure to sildenafil was found to pre-
vent and reverse cardiac hypertrophy in mouse hearts ex-
posed to sustained pressure overload.198 Most recently, PDE5
was also shown to contribute to intracellular cGMP compart-
mentation in cardiac myocytes (Figure 2).145 Indeed, using
the recombinant CNG channel approach to measure subsar-
colemmal cGMP concentration in adult rat ventricular myo-
cytes, sildenafil produced a dose-dependent increase of the
CNG current activated by NO donors but had no effect on the
current elicited by ANP. Therefore, PDE5 exerts a specific
spatiotemporal control on the pool of intracellular cGMP
synthesized by sGC but not that generated by pGC, which, as
discussed above, is under the exclusive control of PDE2.145
This could be either because PDE5 is more closely compart-
mentalized with sGC than pGC (Figure 2), or because PKG,
which activates PDE5,82 is compartmentalized with sGC but
not pGC. Therefore, differential spatiotemporal distributions
of cGMP may contribute to the specific effects of NPs and
NO donors on cardiac function.58 Inasmuch as these results
apply to vascular smooth muscle, they may help to explain
why sildenafil and other PDE5 inhibitors are contraindicated
in men who use nitrate medications.59–61,199,200
Cooperative Role of PDE Isoforms
In many examples, more than 1 PDE isoform is involved in
controlling the cAMP or cGMP concentration at any given
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intracellular location inside a cardiomyocyte. For instance, in
the case of cGMP, both PDE2 and PDE5 were found to
control the subsarcolemmal concentration of cGMP on acti-
vation of sGC by NO donors in rat cardiomyocytes as
demonstrated by selective inhibition of each PDE isoform.
Indeed, EHNA or sildenafil used alone raised subsarcolem-
mal cGMP to a lower level as when the 2 inhibitors were
applied together or when both PDEs were blocked by
IBMX.145 Similarly, the activity of cardiac LTCCs or the
force of contraction is affected by the hydrolytic activity of
several PDEs, because inhibition of a single PDE isoform is
insufficient to raise cAMP level enough to activate these
parameters.154,201,202 Real-time measurements of cAMP in
isolated cardiomyocytes using either the FRET-based or the
recombinant CNG channel method have shown that PDE4
and to a lesser extent PDE3 regulate the amplitude of cAMP
response on a -adrenergic stimulation.74,146 The more prom-
inent role of PDE4 versus PDE3 families may partly result
from a larger stimulatory effect of PKA phosphorylation on
the former, providing a faster negative feedback regulation on
cAMP concentration (Figure 1).65,70,74,146,203,204 Indeed,
blockade of PKA strongly increased the cAMP signal at the
membrane on -AR stimulation of adult rat ventricular
myocytes.146
Restore Cyclic Nucleotide Compartments in
Heart Failure? “Act Locally, Think Globally”
Although an acute stimulation of the cAMP pathway is
beneficial for the heart, a sustained activation, as occurs for
instance in transgenic mice with cardiac overexpression of
1-ARs,205 Gs,206 or PKA,207 leads to hypertrophic growth,
ventricular dysfunction and, ultimately, to heart failure.168,208
A similar situation is found in different forms of human
chronic heart failure, which are all associated with elevated
catecholamines.184,209,210 A possible explanation for the
“good” acute and “bad” chronic effects of cAMP may reside
in the capacity of the cell to maintain proper cAMP signaling
microdomains. That capacity may be overwhelmed in a
chronic setting, resulting in a global and deleterious rise in
cAMP.
Can we thus imagine restoring cAMP compartments and
rescuing or preventing the “bad” outcomes of cAMP elevation,
for instance, via local and isoform-specific PDE activation?
Recent studies performed on a transgenic mouse line (AC8TG)
provide some support for this paradigm. In this animal model,
the human neuronal type 8 AC (AC8) protein was specifically
expressed in cardiomyocytes, leading to a 7- and 4-fold increase
in total AC and PKA activity, respectively.211 Unlike the
endogenous cardiac AC5 and AC6 isoforms, which are inhibited
by Ca2, AC8 is activated by Ca2/calmodulin.212 Therefore, one
would expect that at each heart beat, Ca2 influx through LTCCs
or Ca2 release via RyR2 would activate AC8, hence creating a
positive feedback via PKA on both ICa,L and RyR2, which might
cause a detrimental Ca2 overload. Yet, AC8TG mice show no
sign of hypertrophy or cardiomyopathy at up to 3 months of
age.211,213 When examined at the organ level, isolated perfused
hearts from AC8TG mice show an increased heart rate, larger
amplitude of contraction, faster kinetics of contraction and
relaxation as compared with nontransgenic (NTG) mice.213 At
the single cell level, myocytes from AC8TG hearts contract
faster and stronger, develop larger and faster Ca2 transients,
which represent the hallmarks of an improved SR function.213
Therefore, cardiomyocytes from AC8TG mice respond posi-
tively to the enhanced cAMP synthesis by an improved SR
function, similarly to an acute -adrenergic stimulation. But why
do the myocytes not develop Ca2 overload as would be
expected from the continuous stimulation of the cAMP/PKA
pathway? Patch-clamp experiments revealed that basal ICa,L
amplitude was not different in ventricular myocytes isolated
from AC8TG and NTG hearts, indicating that LTCCs in
AC8TG mice were protected from the large amount of cAMP
generated by AC8.213 Surprisingly, on PDE inhibition by IBMX,
a 2-fold larger increase in ICa,L was observed in AC8TG versus
NTG hearts, indicating that cardiac expression of AC8 is
accompanied by a strong compartmentation of the cAMP signal
attributable to PDE activity that shields LTCCs and protects the
cardiomyocytes from Ca2 overload.213 Additional biochemical
experiments confirmed an increase in cAMP/PDE activity and a
rearrangement of PDE isoforms in AC8TG versus NTG
hearts.214 Therefore, through enhanced PDE activity and com-
partmentation, the AC8TG mouse model provides a nice exam-
ple where chronic activation of cAMP pathway only makes the
“good,” not the “evil.” As discussed above, another such
example can be found in animal models with a cardiac-directed
overexpression of AC6.36–39
The concept that cardiac cAMP signaling can produce both
“good” and “bad” effects depending on where within the cell it
is being activated is certainly relevant to all forms of heart
failure, where major alterations in cAMP signaling occur. The
evidences reviewed here demonstrate that physiological cAMP
and cGMP signaling is confined in specific subcellular domains
attributable to local activities of specific PDEs. We believe that
the “good” outcomes, at least for cAMP, require a strict
localized control of the cyclic nucleotide signaling, leading to
activation of only a limited number of substrates; the “bad”
outcomes occur when compartments are disorganized, a situa-
tion likely to exist during the morphological rearrangements that
accompany hypertrophy and heart failure. Therefore, an in-depth
analysis of cyclic nucleotide signaling in pathologic hypertrophy
and heart failure may provide new treatments of heart failure
acting on localized cyclic nucleotide signaling to improve heart
function and clinical outcomes. Activating specific PDEs in
specific compartments, such as PDE4D near RyR2 or PDE2
near LTCCs, or inhibiting other PDEs in other compartments,
such as PDE3A or PDE5 near PLB, may help to restore a normal
cyclic nucleotide signaling and provide new therapeutic strate-
gies against heart failure.103,104,215
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